Flad Architects

Penn State Health began construction in June of 2024 on the fit-out of its comprehensive cancer center in Enola. Designed by Flad Architects, the 43,000-sf facility will ensure that patients can access world-class care delivered by a multidisciplinary team of specialists. The Penn State Health Cancer Center will feature a dedicated entrance on the ground level, inviting social spaces, advanced chemotherapy and radiation suites, and an onsite medical laboratory.

The University of Kentucky broke ground in June of 2024 on the $285 million Agricultural Research Building in Lexington. Designed by BHDP Architecture and Flad Architects, the 263,000-sf facility will serve as the central research hub for the Martin-Gatton College of Agriculture, Food, and Environment.

Clemson University is planning to break ground in late 2024 on a $285.5 million facility for the College of Veterinary Medicine. Addressing a nationwide shortage of veterinarians, the 232,500-gsf complex will offer sophisticated learning environments for programs in animal health. The development will support a distributed pedagogical model that prepares students to go directly to local animal hospitals for training and clinical study, instead of spending several years in a teaching hospital.

Pfizer has signed a 15-year lease for 230,000 sf of Class A research space in San Diego to accommodate its growing oncology division. The global pharmaceutical manufacturer will occupy two of the three buildings that are currently under construction at Breakthrough Properties' Torrey View campus. Leading-edge wet labs will advance the creation of novel therapies, accompanied by flexible offices and collaboration spaces.

The University of Wisconsin-Madison opened a 145,000-sf expansion of the School of Veterinary Medicine in November of 2023. Designed by Flad Architects and Foil Wyatt Architects & Planners, the three-story addition connects to the original building at each level, doubling the size of the small animal hospital and tripling the space dedicated to infectious disease research. Laboratories for basic discovery are complemented by ABSL-3, BSL-3, and BSL-2 environments for working with influenza, SARS-CoV-2, Ebola, and more.